Cover Image
市場調查報告書

日本煙草產業:產品平台分析

Japan Tobacco Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 251680
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
日本煙草產業:產品平台分析 Japan Tobacco Inc. - Product Pipeline Review - 2014
出版日期: 2014年12月10日 內容資訊: 英文 49 Pages
簡介

日本煙草產業 (JT)是全球第3大香煙廠商。不只香煙,在加工食品及製藥產業領域也活絡地發展其事業。製藥部門目前正在開發HIV感染疾病和C型肝炎,血脂異常症,高磷酸鹽血症,第二型糖尿病,貧血症,自體免疫疾病,過敏性疾病等疾病的治療藥。

本報告提供日本煙草產業的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

日本煙草產業的基本資料

日本煙草產業概要

  • 主要資訊
  • 企業資料

日本煙草產業:R&D概要

  • 主要的治療範圍

日本煙草產業:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

日本煙草產業:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

日本煙草產業:藥物簡介

  • (elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide)
  • TO-206
  • JTT-851
  • JTZ-951
  • JTE-051
  • JTE-052
  • JTK-351
  • JTT-251
  • JTT-252
  • OR-1050
  • Vaccine for Cedar Pollen Allergy

日本煙草產業:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

日本煙草產業:最近的開發平台趨勢

日本煙草產業:暫停中的計劃

日本煙草產業:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • JTK-652
    • JTT-553
    • JTV-803
    • dalcetrapib
    • elvitegravir
    • encaleret
    • granotapide
    • JTE-607
    • JTK-003
    • JTK-656
    • JTK-853
    • JTS-653
    • JTT-302
    • JTT-551
    • JTT-552
    • JTT-651
    • JTT-654
    • MEDI-570

日本煙草產業:企業發表

日本煙草產業:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06599CDB

Summary

Global Markets Direct's, 'Japan Tobacco Inc. - Product Pipeline Review - 2014', provides an overview of the Japan Tobacco Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Japan Tobacco Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Japan Tobacco Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Japan Tobacco Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Japan Tobacco Inc.'s pipeline products

Reasons to buy

  • Evaluate Japan Tobacco Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Japan Tobacco Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Japan Tobacco Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Japan Tobacco Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Japan Tobacco Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Japan Tobacco Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Japan Tobacco Inc. Snapshot
    • Japan Tobacco Inc. Overview
    • Key Information
    • Key Facts
  • Japan Tobacco Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Japan Tobacco Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Japan Tobacco Inc. - Pipeline Products Glance
    • Japan Tobacco Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Japan Tobacco Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Japan Tobacco Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Japan Tobacco Inc. - Drug Profiles
    • (elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TO-206
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JTT-851
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JTZ-951
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JTE-051
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JTE-052
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JTK-351
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JTT-251
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JTT-252
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OR-1050
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Cedar Pollen Allergy
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Japan Tobacco Inc. - Pipeline Analysis
    • Japan Tobacco Inc. - Pipeline Products by Target
    • Japan Tobacco Inc. - Pipeline Products by Route of Administration
    • Japan Tobacco Inc. - Pipeline Products by Molecule Type
    • Japan Tobacco Inc. - Pipeline Products by Mechanism of Action
  • Japan Tobacco Inc. - Recent Pipeline Updates
  • Japan Tobacco Inc. - Dormant Projects
  • Japan Tobacco Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • JTK-652
      • JTT-553
      • JTV-803
      • dalcetrapib
      • elvitegravir
      • encaleret
      • granotapide
      • JTE-607
      • JTK-003
      • JTK-656
      • JTK-853
      • JTS-653
      • JTT-302
      • JTT-551
      • JTT-552
      • JTT-651
      • JTT-654
      • MEDI-570
  • Japan Tobacco Inc. - Company Statement
  • Japan Tobacco Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Japan Tobacco Inc., Key Information
  • Japan Tobacco Inc., Key Facts
  • Japan Tobacco Inc. - Pipeline by Indication, 2014
  • Japan Tobacco Inc. - Pipeline by Stage of Development, 2014
  • Japan Tobacco Inc. - Monotherapy Products in Pipeline, 2014
  • Japan Tobacco Inc. - Combination Treatment Modalities in Pipeline, 2014
  • Japan Tobacco Inc. - Partnered Products in Pipeline, 2014
  • Japan Tobacco Inc. - Partnered Products/ Combination Treatment Modalities, 2014
  • Japan Tobacco Inc. - Out-Licensed Products in Pipeline, 2014
  • Japan Tobacco Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • Japan Tobacco Inc. - Phase III, 2014
  • Japan Tobacco Inc. - Phase II, 2014
  • Japan Tobacco Inc. - Phase I, 2014
  • Japan Tobacco Inc. - Preclinical, 2014
  • Japan Tobacco Inc. - Pipeline by Target, 2014
  • Japan Tobacco Inc. - Pipeline by Route of Administration, 2014
  • Japan Tobacco Inc. - Pipeline by Molecule Type, 2014
  • Japan Tobacco Inc. - Pipeline Products by Mechanism of Action, 2014
  • Japan Tobacco Inc. - Recent Pipeline Updates, 2014
  • Japan Tobacco Inc. - Dormant Developmental Projects,2014
  • Japan Tobacco Inc. - Discontinued Pipeline Products, 2014
  • Japan Tobacco Inc., Subsidiaries

List of Figures

  • Japan Tobacco Inc. - Pipeline by Top 10 Indication, 2014
  • Japan Tobacco Inc. - Pipeline by Stage of Development, 2014
  • Japan Tobacco Inc. - Monotherapy Products in Pipeline, 2014
  • Japan Tobacco Inc. - Partnered Products in Pipeline, 2014
  • Japan Tobacco Inc. - Out-Licensed Products in Pipeline, 2014
  • Japan Tobacco Inc. - Pipeline by Top 10 Target, 2014
  • Japan Tobacco Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Japan Tobacco Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Japan Tobacco Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top